Skip to main content
Open this photo in gallery:

Merck & Co. reported quarterly results on Thursday.Mel Evans/The Associated Press

Merck & Co Inc said on Thursday it would take a bigger hit to sales this year than previously expected due to a resurgence in COVID-19 cases that has hurt demand for drugs that need to be given by doctors.

The pandemic is expected to shave 3 per cent from overall sales, more than the previously projected 2 per cent, after it resulted in a $600 million hit to Merck’s first-quarter sales.

Merck shares fell 3.1 per cent to $74.73 after the company also missed first-quarter earnings estimates.

The surge in COVID-19 cases in the quarter took a particularly heavy toll on Merck’s sales as roughly two-thirds of its products are hospital administered, and a lack of routine health checkups likely led to lower detection of other diseases.

Merck said cancer screenings have been disrupted since the beginning of the pandemic, causing a lower number of patients to start treatment with drugs such as Keytruda, its blockbuster immunotherapy.

“With the rollout of the COVID vaccines, especially among the elderly where cancer incidence is highest, along with increased awareness campaigns, we believe screenings and diagnosis will soon return to normal levels,” said Frank Clyburn, president of Merck’s human health business.

The company also saw a decline in the use of its vaccines and missed routine vaccinations during the pandemic, hurt by government recommendations to avoid other shots in close proximity to getting the COVID-19 vaccines.

Sales of Gardasil, a vaccine to prevent cancers caused by the human papillomavirus, tumbled 16.4 per cent to $917 million in the quarter, hurt by lower demand in the United States, Europe and China.

Sales of Pneumovax to prevent pneumococcal pneumonia and other infections caused by similar bacteria plunged 33 per cent.

The company said it expects the impact to vaccine sales to persist during the first half of 2021.

Merck did not provide any update on when it would start production of Johnson & Johnson’s COVID-19 vaccine in a deal arranged by the U.S. government to help increase supplies of the one-dose shot.

Keytruda sales rose 18.7 per cent to $3.90 billion, but missed analysts’ estimates of $3.98 billion. Sales of Bristol Myers Squibb Co’s rival drug Opdivo fell 3 per cent in the quarter and also missed analyst estimates.

Merck has “the wrong portfolio for a pandemic,” said Citi analyst Andrew Baum, noting its dependence on vaccines and Keytruda.

Excluding items, the company earned $1.40 per share, missing the average analyst estimate by 23 cents, according to IBES data from Refinitiv.

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Report an editorial error

Report a technical issue

Tickers mentioned in this story

Study and track financial data on any traded entity: click to open the full quote page. Data updated as of 28/03/24 7:00pm EDT.

SymbolName% changeLast
MRK-N
Merck & Company
+0.15%131.95

Follow related authors and topics

Authors and topics you follow will be added to your personal news feed in Following.

Interact with The Globe